3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
17
Gynecologic
2
Tumor-Agnostic
1
Thoracic
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Paclitaxel
575
Carboplatin
521
Cisplatin
351
Bevacizumab
252
pembrolizumab
228
Gemcitabine
157
Topotecan
128
Cyclophosphamide
128
liposomal doxorubicin
127
olaparib
120
Taxes
113
Radiotherapy
110
Docetaxel
94
Brachytherapy
89
Doxorubicin
84
Drug Therapy
81
niraparib
75
Nivolumab
71
Magnetic Resonance Spectroscopy
71
Specimen Handling
65
fludarabine
57
Biopsy
55
Hyperthermic Intraperitoneal Chemotherapy
53
Filgrastim
52
Letrozole
50
Oxaliplatin
48
durvalumab
47
Immunoglobulin G
47
atezolizumab
46
Platinum
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
AZD9833
×
Gynecologic
×
Clear all
NCT06188520
2026-05-11
CYCAD-1
AstraZeneca
Phase 1/2
Recruiting
564 enrolled
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled